CURX — Curanex Pharmaceuticals Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2025942 ·
Last close
$0.20
Market Cap
$5.81M
52W High
$0.41
52W Low
$0.18
ADV30
75,347
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,183,359 | -3,150,228 | 8,411,292 | 4,018,574 | 332,644 |
| Dec 2025 | 0 | — | -3,092,639 | -3,073,118 | 11,580,124 | 4,973,134 | 361,040 |
| Sep 2025 | 0 | — | -951,327 | -954,059 | 14,478,157 | 5,830,537 | 185,955 |
| Jun 2025 | 0 | — | -57,658 | -60,346 | 787,174 | 108,862 | 481,743 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,289,064
Investing CF
—
Financing CF
$15,108,695
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.16
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-7,997,783
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-7,230,570
Pretax Income TTM
$-7,237,751
Interest Exp TTM
$7,181
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -4,239,076 | -4,225,106 | 11,580,124 | 361,040 | — | -10,484,452 |
| Dec 2024 | 0 | -290,386 | -361,506 | 517,935 | 14,575 | — | -555,575 |
| Dec 2023 | 0 | -19,298 | -19,198 | 74,366 | 14,276 | — | -120 |
| Dec 2022 | 26,000 | -20,233 | -20,233 | 10,232 | 0 | — | 3,336 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | $5.81M | $2.54 | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $5.74M | $0.44 | — |
| PCSA | Processa Pharmaceuticals, Inc. | $5.95M | $2.15 | — |
| GELS | Gelteq Ltd | $5.57M | $0.52 | — |
| NCNA | NuCana plc | $5.49M | $1.32 | — |
News headlines (Yahoo Finance, 1h cache)
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
2026-05-14 12:53 · Yahoo
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
2026-04-08 11:47 · Yahoo
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
2026-04-06 13:17 · Yahoo
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeuti
2026-04-02 12:07 · Yahoo
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
2026-03-30 21:35 · Yahoo
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
2026-03-18 12:00 · Yahoo
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
2026-03-12 13:30 · Yahoo
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
2026-03-11 12:00 · Yahoo
Curanex Forms World Class Scientific Advisory Board
2026-03-05 13:00 · Yahoo
Curanex Provides Operational Update on Key Regulatory Milestones
2026-02-25 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.